FITY
Fifty 1 Labs, Inc.·Financial Services
0.00
33.333%(+0.00)
Market OpenLast Updated: — ET
52W L: $0.0052W H: $0.01
FITY NEWS
accessnewswire.com
Apr 15
Fifty 1 Labs, Inc. Accelerates Peptide Biotechnology Push into Musculoskeletal Health
AI-Enabled Discovery and Clinical-Stage Development Target Injury Recovery, Performance, and Tissue Healing VANCOUVER, BC / ACCESS Newswire / April 15, 2026 / Fifty 1 Labs, Inc. (OTC:FITY), powered by its AI initiatives today announced the continued expansion of its biotechnology strategy focused on peptide products, peptide discovery, and clinical research for musculoskeletal ("MSK") health, recovery, and performance. Building on its transition into biotechnology and life sciences, the Company is advancing an integrated platform that combines peptide science, artificial intelligence-enabled discovery, and staged clinical development to address unmet needs across muscle, tendon, ligament, and bone conditions.
accessnewswire.com
Apr 14
Fifty 1 Labs, Inc. Eliminates 612 Million Shares from the Market
Company Retires 1,748,933 Series B Preferred Shares, Permanently Blocking Conversion into 612,126,550 Common Shares - Bought Back with Company Funds VANCOUVER, BC / ACCESS Newswire / April 14, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY), an AI-powered biotechnology company focused on peptide therapeutics, today announced the successful retirement of 1,748,933 shares of its Series B Preferred Stock. This strategic move, completed using the Company's own funds in direct collaboration with the shareholder, permanently removes the potential for approximately 612,126,550 common shares from entering the market.
